GENEVA (AP) – Swiss pharmaceutical company Novartis AG says it has halted clinical trials for a new drug to treat hepatitis after one patient died.
The Basel-based company says it has informed the U.S. Food and Drug Administration of “a small number” of reported cases of pancreatitis and one death in patients who were receiving the drug alisporivir and other medication to treat hepatitis C.
Pancreatitis is an inflammation of the pancreas.
Novartis said in a statement it was notified by the FDA that clinical trials of the drug will be put on hold.
The company reports its first-quarter results on April 24.
Date: April 19, 2012
Source: Associated Press
Filed Under: Drug Discovery